contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Cessatech

The Company has advanced well with its planned activitiesCommercial partnership agreement with Proveca LtdGood progress with Paediatric Safety Study 0202Loan Facility Agreement extended to the...

<div class="abstract">The Company has advanced well with its planned activities<ul><li>Commercial partnership agreement with Proveca Ltd</li><li>Good progress with Paediatric&nbsp;Safety Study 0202</li><li>Loan Facility Agreement extended to the year 2026</li><li>US manufacturing and launch finalization in process</li></ul></div><p>Cessatech A/S ("Cessatech" or the "Company") today releases its results for the period 1 July - 30 September 2024. The third quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings &amp; Reports.&nbsp;</p>Third quarter financial results 2024 (1 July - 30 September):<ul><li>Net Revenue was KDKK 3.356</li><li>Operating result was KDKK -925</li><li>Net result was KDKK -1.132</li><li>Cash at bank end of the period was KDKK 5.944</li><li>Earnings per share* was KDKK -0,06</li><li>Solidity** was 77%</li></ul><p>*Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 30 September 2024 amounted to 17.425.094 shares, the average number of shares during the third quarter was 17.425.094&nbsp;<br>**Solidity: Total equity divided by total capital and liability</p><p>Comment from CEO, Jes Trygved:<br>The commercialization and partnership agreement with Proveca Ltd, was a major effort and milestone for the company. A process that started last year, identifying the right partner for the registration and commercialization of CT001 for Europe and selected markets in rest of the world, has materialized and we are very pleased with the outcome. We are also pleased to have seen very good progress with the Paediatric Safety Study 0202, which has now reached the 50% enrolment mark. We are still spending significant time and effort on the manufacturing and launch of CT001 for the US market, this is another major milestone, and we hope soon to have a final launch date. Thanks for a great effort by the team !</p>

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!